Press Releases Biogen Inc.

Equities

BIIB

US09062X1037

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
208.9 ^USD	+3.18%		+7.47%	-19.27%

Apr. 26	Guggenheim Adjusts Price Target on Biogen to $255 From $275	MT
Apr. 25	Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®	Apr. 25	GL
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA	Mar. 31	PR
Biogen : Update on European Medicines Agency Review of Lecanemab Marketing Authorization Application	Mar. 22	PU
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	Mar. 21	BU
InvestorBrandMedia: Anixa Biosciences (NASDAQ:ANIX) Gains Attention for Its Innovative Cancer Therapies Amid Biopharma Sector Growth	Mar. 20	AQ
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	Mar. 14	BU
Biogen : to Participate in the Stifel 2024 Virtual CNS Days	Mar. 12	PU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Biogen Inc. - BIIB	Mar. 11	PR
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy	Mar. 06	GL
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy	Mar. 06	AQ
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting	Mar. 04	GL
BYOOVIZ Is Confusing With BEOVU: Federal Court Finds Violation Of Novartis' Trademark Rights	Mar. 04	AQ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Biogen Inc. - BIIB	Mar. 03	PR
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors	Feb. 23	BU
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP	Feb. 23	GL
Law Offices of Howard G. Smith Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors	Feb. 22	BU
The Law Offices of Frank R. Cruz Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors	Feb. 21	BU
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia	Feb. 12	GL
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia	Feb. 12	AQ
Aptar Signs Enterprise Agreement with Biogen to Operate and Develop Digital Health Solutions	Feb. 12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Biogen Inc.

Equities

BIIB

US09062X1037

Press Releases

Filters